Cardiomyopathy

A recent study examined the confounding effect of mortality on the frequency of CV-related hospitalization in patients in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). The impact of tafamidis on CV-related hospitalization was underestimated in the ATTR-ACT, according to researchers. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease caused by the buildup of amyloid...

In patients stabilized on tafamidis, SGLT2 inhibitors may be beneficial for improving outcomes of transthyretin amyloid cardiomyopathy (ATTR-CM). Treatment with dapagliflozin was found to be well-tolerated in patients with ATTR-CM. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart disease that can be fatal. In recent years, more and more people have been diagnosed and subsequently hospitalized...

Patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) are at risk of cardiovascular comorbidities, including atrial fibrillation and flutter. Routine ambulatory monitoring in patients with ATTR-CM could help drive the use of anticoagulation to prevent strokes. Heart complications, such as heart failure, are common in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM). Atrial fibrillation and flutter (AF/AFL), in...

The awareness and diagnosis of wild‐type transthyretin amyloid cardiomyopathy (ATTRwt CM) is challenging, despite ATTRwt being more common than previously thought. Screening is necessary for early detection and diagnosis of ATTRwt CM, as well as for timely treatment of the disease. The clinical characteristics of wild‐type transthyretin amyloid cardiomyopathy (ATTRwt CM) can vary among affected...

Heart failure, among other cardiovascular problems, is a typical manifestation of transthyretin amyloidosis cardiomyopathy (ATTR-CM). The prevalence of ATTR-CM as a phenotype of heart failure is often underestimated. Heart failure with preserved ejection fraction (HFpEF) affects more than half of patients with heart failure. The phenotypes of heart failure can vary, and treatment modalities are...

Medication adherence is a critical aspect of treating patients with ATTR-CM and ensuring optimal outcomes. Research suggests that many patients with ATTR-CM are adherent to treatment with tafamidis, partly due to the availability of a one-tablet dose. Tafamidis is the first FDA-approved treatment for ATTR-CM that has been shown to help reduce disease progression and...

An early diagnosis of transthyretin amyloidosis (ATTR) is key for managing the disease and preventing costly complications. One study suggests that cardiovascular symptoms and increased hospitalizations are a potential way to identify the disease early. Transthyretin amyloidosis (ATTR) is a progressive condition characterized by the buildup of amyloid in the organs and tissues. It can...

Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are faced with different possibilities for treating their symptoms and underlying disease. However, treatment options may vary depending on the severity of the disease, the cost of the treatment, and other factors. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive disease that primarily affects the heart, although it can...

Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare, age-related, debilitating disease. In particular, the wild-type (ATTRwt) is often diagnosed in older patients who also present symptoms of other comorbidities. One review, published in Frontiers in Cardiovascular Medicine, discussed the challenges when diagnosing older patients with ATTR-CM. 13% of patients over 60 hospitalized with heart failure with...